Abstract
摘要
相似文献
1
2004 antiretroviral drug guide.
IAPAC Mon. 2004 Oct;10 Suppl 1:8-35.
2
13th annual HIV drug guide.
Posit Aware. 2009 Mar-Apr;20(2):28-55.
3
12th annual HIV drug guide.
Posit Aware. 2008 Jan-Feb;19(1):19-48.
4
HIV treatment and the nonclinician: getting your bearings.
HRSA Careaction. 2007 Jan:1-12.
5
Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int. 2008 Aug;17(96):135-7.
6
Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
Prescrire Int. 2009 Jun;18(101):104.
7
[Antiretroviral therapy of HIV infection. German-Austrian guidelines (position in September 2008)].
Dtsch Med Wochenschr. 2009 Jan;134 Suppl 1:S4-15. doi: 10.1055/s-0028-1123965. Epub 2009 Jan 26.
8
[Metabolic side effects of antiretroviral therapy].
Ned Tijdschr Geneeskd. 2008 May 31;152(22):1260-4.
9
New antiretroviral agents and the complexity of treatment practices.
J HIV Ther. 2008 Jun;13(2):25-6.
10
[HIV-1 protease inhibitors. Why, when, and how?].
Enferm Infecc Microbiol Clin. 1998 Nov;16(9):393-4.
Zotero 插件